The objective of this study was to develop novel water-based drug-in-adhesive pressure-sensitive adhesives (PSAs) patches for the transdermal delivery of ketoprofen, employing poly(N-vinylpyrrolidone-co-acrylic acid) copolymer (PVPAA) and poly(methyl vinyl ether-alt-maleic anhydride) (PMVEMA) as the main components. The polymers were crosslinked with tartaric acid and dihydroxyaluminium aminoacetate using various polymer ratios. Ketoprofen was incorporated into the PVPAA/PMVEMA PSAs during the patch preparation. The physicochemical properties, adhesive properties, drug content, release profile, and skin permeation of the patches were examined. Moreover, the in vivo skin irritation and skin adhesion performance in human volunteers were evaluated. The patches prepared at a weight ratio of PVPAA/PMVEMA of 1:1 presented the highest tacking strength, with desirable peeling characteristics. The ketoprofen-loaded PVPAA/PMVEMA patches exhibited superior adhesive properties, compared to the commercial patches, because the former showed an appropriate crosslinking and hydrating status with the aid of a metal coordination complex. Besides, the permeated flux of ketoprofen through the porcine skin of the ketoprofen-loaded PVPAA/PMVEMA patches (4.77 ± 1.00 µg/cm2/h) was comparable to that of the commercial patch (4.33 ± 0.80 µg/cm2/h). In human studies, the PVPAA/PMVEMA patches exhibited a better skin adhesion performance, compared with the commercial patches, without skin irritation. In addition, the patches were stable for 6 months. Therefore, these novel water-based PSAs may be a potential adhesive for preparing drug-in-adhesive patches.

Progesterone (P4) is a neurosteroid hormone synthesized in both males and females, it is widely used in reproductive health and hormone replacement therapy. The aim of this study was to develop microemulsions (ME) and optimization of P4 microemulsion using a simplex lattice mixture design for enhancing the transdermal delivery of P4. Pseudo-ternary phase diagrams were generated to find the optimal ratio of the microemulsion constituents. The solubilities of P4 in different oils, surfactants, and co-surfactants were determined. The ME formulations of P4 were then prepared and optimized by simplex lattice mixture design. Each ME formulation was characterized for size, PDI, zeta potential, drug content, in vitro permeation study, and drug permeation in porcine skin. The result showed that the optimal ME formulation composed of 34.97 %w/w eugenol as the oil phase, 18.35 %w/w Labrasol® as the surfactant, 36.69 %w/w ethanol as the cosurfactant, and 10.00% w/w water containing HPβCD (1.0 M). The optimized ME showed an appropriate size of about 178 ± 42 nm with a low polydispersity index (PDI) and almost neutral charge. The drug content of the optimized ME was about 19.9 ± 0.6 %w/w. The results of in vitro permeability showed that the optimized ME formulation was significantly higher than the drug suspension. Moreover, the P4 from the optimized ME was able to be deposited in the dermis (1.07 mg) at a higher extent than in the stratum corneum (0.65 mg). In conclusion, this study explored a formulation approach to improve the transdermal permeation of P4.

Ocular drug delivery by topical application is the most popular for the treatment of ocular diseases. However, a number of inherent anatomical and physiological ocular barriers limit the bioavailability of the drug administered by topical application. To overcome this limitation, dissolving polymeric microneedles (dMNs) have been used to create transport pathways and enhance the permeability of ocular drugs with minimal invasion. The aim of this study was to design and evaluate Optimized dMNs for ocular delivery of a hydrophilic drug using a computational design strategy. Polyvinyl alcohol/hyaluronic acid mixture was used as the dMN-forming polymers. A micromolding technique was used to fabricate the dMNs. The dMNs were evaluated for physical appearance using a digital microscope, mechanical strength using a texture analyzer. Moreover, the dissolution time, penetration depth, and permeation study on the porcine corneal tissues were investigated. The results showed that the optimal dMNs formulation was 20%PVA and 5%HA in a 1:5 weight ratio. The physical appearance showed conical microneedles with an average 601.23 ± 1.01 μm in height and 300.02 ± 0.23 μm in the base width. The optimal dMNs showed a maximum tolerance force of about 33.70 ± 0.30 N and created micro-channels on corneal tissues surface with the depth about 134.71±16.51 μm. The optimal dMNs can be completely dissolved in the corneal tissue within 3 min with high % permeation and flux of fluorescein sodium about 10.10 ± 0.55% and 14.21 ± 1.45 μg/cm2/h, respectively. In conclusion, the optimal dMNs showed high efficiency to enhance ocular delivery of the hydrophilic drug with safe and minimal invasion for ocular tissue.

Successful COVID-19 prevention requires additional measures beyond vaccination, social distancing, and masking. A nasal spray solution containing human IgG1 antibodies against SARS-CoV-2 (COVITRAP™) was developed to strengthen other COVID-19 preventive arsenals. Here, we evaluated its pseudovirus neutralization potencies, preclinical and clinical safety profiles, and intranasal SARS-CoV-2 inhibitory effects in healthy volunteers (NCT05358873). COVITRAP™ exhibited broadly potent neutralizing activities against SARS-CoV-2 with PVNT50 values ranging from 0.0035 to 3.1997 μg/ml for the following variants of concern (ranked from lowest to highest): Alpha, Beta, Gamma, Ancestral, Delta, Omicron BA.1, Omicron BA.2, Omicron BA.4/5, and Omicron BA.2.75. It demonstrated satisfactory preclinical safety profiles based on evaluations of in vitro cytotoxicity, skin sensitization, intracutaneous reactivity, and systemic toxicity. Its intranasal administration in rats did not yield any detected circulatory levels of the human IgG1 anti-SARS-CoV-2 antibodies at any time point during the 120 hours of follow-up. A double-blind, randomized, placebo-controlled trial (RCT) was conducted on 36 healthy volunteers who received either COVITRAP™ or a normal saline nasal spray at a 3:1 ratio. Safety of the thrice-daily intranasal administration for 7 days was assessed using nasal sinuscopy, adverse event recording, and self-reporting questionnaires. COVITRAP™ was well tolerated, with no significant adverse effects in healthy volunteers for the entire 14 days of the study. The intranasal SARS-CoV-2 inhibitory effects of COVITRAP™ were evaluated in nasal fluids taken from volunteers pre- and post-administration using a SARS-CoV-2 surrogate virus neutralization test. SARS-CoV-2 inhibitory effects in nasal fluids collected immediately or six hours after COVITRAP™ application were significantly increased from baseline for all three variants tested, including Ancestral, Delta, and Omicron BA.2. In conclusion, COVITRAP™ was safe for intranasal use in humans to provide SARS-CoV-2 inhibitory effects in nasal fluids that lasted at least six hours. Therefore, COVITRAP™ can be considered an integral instrument for COVID-19 prevention.

No abstract